diabetic nephropathy
Conditions
Interventions
Canagliflozin 100mg per day taken orally for 1year
Sponsors
Keio University, School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.patients with diabetic nephropathy which is worse than stage2 2.eGFR higher than 45ml/min/1.73m2 3.free of kidney disease other than diabetic nephropathy 4.HbA1c higher than 6.5 percent and lower than 10.0 percent 5.patients who are on 8weeks of dietary cure and exercise therapy before the study, or patients who are taking oral diabetic medicine other than Canagliflozin 6.patients who recieved enough explanation to understand about the study and signed on the agreement document by whose own will
Exclusion criteria
Exclusion criteria: 1.patiens whose eGFR declined more than 25% during the observation period 2.patients with fasting blood glucose higher than 250mg/dl 3.patients who has been on dialysis or who went through renal transplantation 4.patients with type 1 diabetes or secondary diabetes 5.patients who has taken other investigational drugs within 3months of the beginning of this study 6.patients who fall under contraindication of Canagliflozin 7.patients whom the doctor decided unsuitable for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the microbiome of patients with diabetic nephropaty | — |
Countries
Japan
Contacts
Public ContactAyumi Matsui
Keio University, School of Medicine Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine
Outcome results
None listed